GLOBAL NON OPIOID PAIN TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• On February 05, 2024, Hikma Pharmaceuticals PLC, a multinational pharmaceutical company, announced the launch of COMBOGESIC IV (acetaminophen and ibuprofen) injection in the U.S. COMBOGESIC IV is an intravenous, opioid-free pain reliever that contains 1,000 mg of acetaminophen and 300 mg of ibuprofen, a nonsteroidal anti-inflammatory drug.
• In December 2023, Vertex Pharmaceuticals, a pharmaceutical company, announced that a non-opioid painkiller significantly reduced pain in diabetic patients suffering from chronic nerve pain in a mid-stage trial, fueling efforts to develop a medication free of the risk of addiction. The research looked at the medicine VX-548 in individuals who had diabetic peripheral neuropathy, a kind of nerve damage caused by high blood sugar.
• In October 2023, Hyloris Pharmaceuticals, a Belgium based pharmaceutical company, announced the approval of a potent non-opioid painkiller in the U.S. Maxigesic IV's New Drug Application (NDA) had been authorized by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate pain and as an additional therapy for moderate to severe pain
• In February 2020, GlaxoSmithKline, a pharmaceutical company, announced that the US FDA has approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)-arthritis pain reliever) as an over-the-counter (OTC) product for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle, or knee in adults (18 years and older).